What Has Been the Growth Trajectory of the Hematopoietic Stem Cell Transplantation Market?
The hematopoietic stem cell transplantation market has seen considerable growth due to a variety of factors.
•In recent times, there has been substantial growth in the market size for hematopoietic stem cell transplantation. The market is forecasted to expand from a value of $4.68 billion in 2024 to $5.12 billion in 2025, indicating a compound annual growth rate (CAGR) of 9.3%.
The notable growth during the previous period is linked to the development of early transplantation techniques, a controlled number of indications and donor sources, progress in conditioning regimens, the introduction of allogeneic transplants, and regulatory accomplishments.
What Does the Future Hold for the Hematopoietic Stem Cell Transplantation Market?
The hematopoietic stem cell transplantation market is expected to maintain its strong growth trajectory in upcoming years.
• It is anticipated that the market size of hematopoietic stem cell transplantation will experience a swift expansion in the coming years, reaching "$7.73 billion by 2029 with a compound annual growth rate (CAGR) of 10.9%.
The growth anticipations for the forecast period are derived from factors such as broadened treatment indications, diversification of donor sources, the introduction of personalized medicine and genomics, modifications in regulations and guidelines, and expansion and increased accessibility in the market. Significant trends projected for the forecast period encompass progress in transplantation methods, wider treatment indications, the rise of cellular therapies, donor diversification, and a precision medicine approach.
What Are the Critical Driver Fuelling the Hematopoietic Stem Cell Transplantation Market's Growth?
A rise in the occurrence of blood cancer is predicted to spur the hematopoietic stem cell transplantation market's expansion. Blood cancers, a collection of malignancies affecting the growth and function of blood cells, include leukemia, lymphoma, and myeloma. Hematopoietic stem cell transplantation is typically employed to treat these types of cancer by substituting the damaged stem cells and bone marrow cells due to cancer. The replacement stem cells can then relocate to the bone marrow where they start producing new blood cells, which in turn contributes to the growth of the hematopoietic stem cell transplantation market. As per the data shared by Blood Cancer UK, a non-profit based in the UK, and published in August 2022, blood cancer is the sixth most common cancer in the UK with 41,000 cases diagnosed annually. One in 16 men and one in 22 women in the country will be diagnosed with this disease at some point in their lives, pushing yearly expected cases to around 250,000 in 2022. Notably, blood cancer also impacts over 500 children under 15 every year, with 400 suffering from pediatric leukemia and 100 from lymphoma. Thus, the higher prevalence of blood cancer acts as a significant trigger for the hematopoietic stem cell transplantation market.
How Is the Hematopoietic Stem Cell Transplantation Market segmented?
The hematopoietic stem cell transplantation market covered in this report is segmented –
1) By Type: Allogeneic, Autologous
2) By Indication: Leukemia, Lymphatic Disorder, Myeloma, Other Non-Malignant Disorders
3) By Application: Bone Marrow Transplant, Peripheral Blood Stem Cell Transplant, Cord Blood Transplant
4) By End User: Hospital Pharmacy, Retail Pharmacy, Specialty Clinics
Subsegments:
1) By Allogeneic: Matched Related Donor Transplantation, Matched Unrelated Donor Transplantation, Cord Blood Transplantation
2) By Autologous: Peripheral Blood Stem Cell Transplantation, Bone Marrow Stem Cell Transplantation
Pre-Book The Hematopoietic Stem Cell Transplantation Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Hematopoietic Stem Cell Transplantation Market?
The rising trend in the hematopoietic stem cell transplantation market is the approval of products. The dominant companies in this sector are focusing on gaining product approvals to maintain their market standing. Take for example Priothera Ltd., a late-stage biotechnology firm based in Ireland. In April 2022, they achieved clearance from the United States Food and Drug Administration (FDA) for an Investigational New Drug (IND) to initiate a phase IIb/III allogeneic hematopoietic stem cell transplant (HSCT) research trial with mocravimod on patients suffering from Acute Myeloid Leukemia (AML). Mocravimod is an artificially produced Sphingosine 1-phosphate receptor (S1PR) modulator, also identified as KRP203. Both phase I and II trials have analyzed the safety, tolerability, and efficacy of this novel experimental drug for multiple autoimmune diseases.
Who Are the Key Players in the Hematopoietic Stem Cell Transplantation Market?
Major companies operating in the hematopoietic stem cell transplantation market include:
• Pluristem Therapeutics Inc.
• Lonza Group AG
• Escape Therapeutics Inc.
• Regen Biopharma Inc.
• Bluebird Bio Inc.
• CellGenix GmbH
• CBR Systems Inc.
• Merck KGaA
• Cord Blood Corporation
• Kiadis Pharma NV
• Marker Therapeutics Inc.
• Taiga Biotechnologies Inc.
• Takeda Pharmaceutical Company Limited
• Talaris Therapeutics Inc.
• ViaCord LLC
• ScienCell Research Laboratories Inc.
• BiolineRx
• Stemcell Technologies Inc.
• ThermoGenesis Holdings Inc.
• MEDIPOST Co. Ltd.
• Anterogen. Co. Ltd.
• Pharmicell Inc.
• JCR Pharmaceuticals Co. Ltd.
• Holostem Terapie Avanzate Srl
• Regrow Biosciences Pvt Ltd.
• Stempeutics Research Pvt Ltd.
What Is The Most Dominant Region In The Hematopoietic Stem Cell Transplantation Market?
North America was the largest region in the hematopoietic stem cell transplantation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global hematopoietic stem cell transplantation market during the forecast period. The regions covered in the hematopoietic stem cell transplantation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
